Diarrhea and vomiting followed similar patterns but with shorter individual episode durations
Other TRIUMPH Trials Additional Phase 3 trials in the TRIUMPH program are ongoing: TRIUMPH-1: Retatrutide in obesity (general population), results expected 2026 TRIUMPH-2: Retatrutide in type 2 diabetes, results expected 2026 TRIUMPH-3: Retatrutide cardiovascular outcomes trial, results expected 2027 Visualize Your Retatrutide Journey See how retatrutide builds up in your system over time and compare different dosing protocols
Your doctor will likely taper your current dose and introduce Retatrutide at a low starting amount to reduce the risk of side effects during the transition
This combination controls blood sugar, reduces appetite, and promotes weight loss
For individuals seeking medically supervised weight management in the UK, MHRA-authorised options are available
Family Practice Providers Internal Medicine Providers Specialist Providers Medical Billing Leadership REGISTRATION DETAILS The webinar will be held on Wednesday, October 9, 2024 at 12 p.m
